Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Union Pacific Corporation (UNP) Price & Performance

Cytokinetics IncTrade
Union Pacific CorporationTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Union Pacific Corporation — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Union Pacific Corporation trades at $292.17 (market cap $173.99B). The key difference: Union Pacific Corporation is far larger — about 16.4× Cytokinetics Inc's market cap, and Union Pacific Corporation pays a 1.94% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKUNP
Market Cap
$10.63B$173.99B
Sector
TechnologyIndustrials
52-Week High
$87.26$307.32
52-Week Low
$34.31$214.91
Enterprise Value
$10.74B$203.04B
Dividend Yield
1.94%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.

The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.

Union Pacific Corporation

Union Pacific (UNP) trades at $294.24, up 0.68% with strong fundamentals including 28.85% net margins and 39.7% ROE. The stock shows bullish momentum with Q2 2026 EPS beating estimates by 4.6% and management raising full-year guidance. Technical indicators are neutral overall, with the current price near resistance at $294. Recent news highlights institutional accumulation and a 3% dividend increase announced July 29, 2026.

Outlook remains positive with analyst consensus target of $334.33 (13.6% upside) and 58.7% buy ratings. Key opportunities include service-led growth driving margin expansion, while risks involve high fuel costs and regulatory scrutiny of the Norfolk Southern merger. The company's strong cash flow generation supports continued dividend growth and capital returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Union Pacific Corporation

Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.

Read more on UNP